Volume 145, Issue 3, Pages 574-582.e1 (September 2013) Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal, Linda Morrow, Hanns–Ulrich Marschall, Mark Kipnes, Luciano Adorini, Cathi I. Sciacca, Paul Clopton, Erin Castelloe, Paul Dillon, Mark Pruzanski, David Shapiro Gastroenterology Volume 145, Issue 3, Pages 574-582.e1 (September 2013) DOI: 10.1053/j.gastro.2013.05.042 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Increased FGF19 and decreased C4 and endogenous bile acid plasma levels and weight in patients with diabetes and NAFLD after treatment with OCA. Data are presented as mean ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001. Statistical significance is based on comparisons of absolute change from baseline between the OCA treatment groups and placebo. Gastroenterology 2013 145, 574-582.e1DOI: (10.1053/j.gastro.2013.05.042) Copyright © 2013 AGA Institute Terms and Conditions
Supplementary Figure 1 Disposition of patients with type 2 diabetes mellitus and NAFLD in the study. Gastroenterology 2013 145, 574-582.e1DOI: (10.1053/j.gastro.2013.05.042) Copyright © 2013 AGA Institute Terms and Conditions